2025
A flexible Bayesian g-formula for causal survival analyses with time-dependent confounding
Chen X, Hu L, Li F. A flexible Bayesian g-formula for causal survival analyses with time-dependent confounding. Lifetime Data Analysis 2025, 31: 394-421. PMID: 40227517, DOI: 10.1007/s10985-025-09652-3.Peer-Reviewed Original ResearchConceptsG-formulaBalance scoresHealth system electronic health recordDiscrete survival dataTime-to-event outcomesPosterior sampling algorithmParametric g-formulaElectronic health recordsBayesian additive regression treesTime-varying treatmentsHypothetical intervention scenariosAdditive regression treesLongitudinal observational studyGeneral classModel misspecificationHealth recordsEmpirical performanceSampling algorithmObservational studySurvival dataIntervention scenariosScoresTreatment strategiesMisspecificationCausality analysis
2024
Bayesian pathway analysis over brain network mediators for survival data
Tian X, Li F, Shen L, Esserman D, Zhao Y. Bayesian pathway analysis over brain network mediators for survival data. Biometrics 2024, 80: ujae132. PMID: 39530270, PMCID: PMC11555425, DOI: 10.1093/biomtc/ujae132.Peer-Reviewed Original ResearchConceptsAccelerated failure time modelFailure time modelBrain connectivityAlzheimer's Disease Neuroimaging Initiative studyMaximum information extractionResponse regressionBayesian approachInformation extractionTime modelSurvival dataNoisy componentsUnique edgeWhite matter fiber tractsNetwork configurationBrain networksInterconnection networksNetworkNetwork mediatorsBrainCorrelation between hospital rates of survival to discharge and long-term survival for in-hospital cardiac arrest: Insights from Get With The Guidelines®-Resuscitation registry
Khera R, Aminorroaya A, Kennedy K, Chan P, Investigators A, Grossestreuer A, Moskowitz A, Ornato J, Churpek M, Starks M, Girotra S, Perman S. Correlation between hospital rates of survival to discharge and long-term survival for in-hospital cardiac arrest: Insights from Get With The Guidelines®-Resuscitation registry. Resuscitation 2024, 202: 110322. PMID: 39029583, PMCID: PMC11390317, DOI: 10.1016/j.resuscitation.2024.110322.Peer-Reviewed Original ResearchRisk-standardized survival ratesIn-hospital cardiac arrestWeighted kappa coefficientResuscitation RegistryLong-term survivalSurvivors of in-hospital cardiac arrestHierarchical logistic regression modelsCardiac arrestIn-HospitalLogistic regression modelsLong-term outcomesSurvival dataKappa coefficientHospital performanceIn-Hospital SurvivalMedicare filesMedicare beneficiariesYears of ageHospitalization ratesPost-discharge survivalHospital dischargeRate of survivalMedicareHospitalRegression modelsA model-free variable screening method for optimal treatment regimes with high-dimensional survival data
Yang C, Cheng Y. A model-free variable screening method for optimal treatment regimes with high-dimensional survival data. Biometrika 2024, 111: 1369-1386. DOI: 10.1093/biomet/asae022.Peer-Reviewed Original ResearchHigh-dimensional survival dataOptimal treatment regimeVariable screening methodClassification problemOutcome-dependent samplingLevel of robustnessSurvival dataNonparametric learning methodKolmogorov-Smirnov approachCensoring distributionTheoretical propertiesModel misspecificationMisclassification error rateLogit lossHinge lossSimulation studyOptimal classifierBinary classificationSelection probabilityLearning methodsError rateRandom forestLung cancer datasetModel assumptionsCancer datasets
2023
Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.
Zhao J, Wong Zhun Hong N, Yap D, Ong R, Sundar R, Lim J, Dawood S. Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Journal Of Clinical Oncology 2023, 41: 1096-1096. DOI: 10.1200/jco.2023.41.16_suppl.1096.Peer-Reviewed Original ResearchProgression free survival benefitTreatment of physician's choiceProgression free survivalMetastatic breast cancerEndocrine therapyESR1 mutationsOverall cohortEstrogen receptorKaplan MeierEstimate time-to-event outcomesHER2-negative metastatic breast cancerOral selective estrogen receptor degraderHER2- metastatic breast cancerSurvival dataTreatment of estrogen receptorSelective estrogen receptor degraderOverall populationCompare survival outcomesIPD meta-analysisMeta-analysisEstrogen receptor degraderOral SERDsPFS differenceCompared to ETFree survivalA censored quantile regression approach for relative survival analysis: Relative survival quantile regression
Williamson J, Lin H, Lyles R. A censored quantile regression approach for relative survival analysis: Relative survival quantile regression. Biometrical Journal 2023, 65: e2200127. PMID: 36939023, DOI: 10.1002/bimj.202200127.Peer-Reviewed Original ResearchConceptsQuantile regression modelQuantile regressionQuantile regression approachPopulation life tablesSurvival dataLife tablesRelative survival dataRelative survival analysisRegression modelsRegression approachQuantilesStudy observationsStudy covariatesStudy participantsCovariatesDemographic variablesEffectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
Yap D, Leone A, Wong N, Zhao J, Tey J, Sundar R, Pietrantonio F. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma. JAMA Oncology 2023, 9: 215-224. PMID: 36480211, PMCID: PMC9857522, DOI: 10.1001/jamaoncol.2022.5816.Peer-Reviewed Original ResearchConceptsAdvanced esophageal squamous cell carcinomaImmune checkpoint inhibitorsEsophageal squamous cell carcinomaSquamous cell carcinomaPD-L1 expressionKaplan-Meier curvesLow PD-L1 expressionFirst-line trialsProgression-free survivalDuration of responsePD-L1Overall survivalCell carcinomaRandomized clinical trialsPooled analysisClinical trialsCheckpoint inhibitorsTumor proportionEffect of immune checkpoint inhibitorsLow programmed death ligand 1Benefit of immune checkpoint inhibitorsHazard ratioSurvival dataFirst-line settingICI-based regimens
2022
KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves
Zhao J, Syn N, Tan B, Yap D, Teo C, Chan Y, Sundar R. KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves. BMC Medical Research Methodology 2022, 22: 93. PMID: 35369867, PMCID: PMC8978435, DOI: 10.1186/s12874-022-01567-z.Peer-Reviewed Original ResearchConceptsMonte Carlo simulationsLimits of errorSubgroup survival dataCarlo simulationsSurvival dataKaplan-MeierKaplan-Meier survival curvesExtensive Monte Carlo simulationsOriginal survival dataFollow-up timeCox proportional hazards modelsSubgroups of clinical interestPublished Kaplan-Meier survival curvesMarginal Cox proportional hazards modelsProportional hazards modelMatched patientsSecondary data analysisSystematic errorsSurvival curvesProportion of missing dataHazards modelClinical interestPatientsPrimary manuscriptsKM plots
2021
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2020
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2710-2718. PMID: 32998946, PMCID: PMC7747688, DOI: 10.1158/1055-9965.epi-20-0490.Peer-Reviewed Original ResearchConceptsCancer recurrence rateRecurrence rateRelative survival dataColorectal cancerSurvival dataColorectal cancer-related deathsDisease-specific survival dataStage II rectal cancerStage III colorectal cancerCancer-specific death ratesStage II colon cancerPopulation-based cancer registriesColorectal cancer interventionDiagnostic time periodsMetastatic recurrence ratesRate 6 monthsNonmetastatic colorectal cancerColorectal cancer recurrenceMonths of diagnosisAnnual recurrence rateEnd Results ProgramCancer-related deathColorectal cancer diagnosisDecision analytic modelMetastatic diseaseCTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM)
Lukas R, Chiocca E, Bush N, Landolfi J, Cavaliere R, Yu J, Kurz S, Demars N, Buck J, Hadar N, Miao J, Loewy J, Wang Y, Gelb A, Cooper L. CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM). Neuro-Oncology 2020, 22: ii39-ii39. PMCID: PMC7650356, DOI: 10.1093/neuonc/noaa215.162.Peer-Reviewed Original ResearchPD-1 inhibitorsImmune-mediated anti-tumor effectsAnti-tumor effectsRecurrent glioblastomaIL-12PD-1Overall survivalFollow-upIncreased PD-1 expressionIL-12 therapyPD-1 expressionPhase 2 trialPhase 1 trialPost-treatment biopsiesGene therapy candidateSurvival dataEndogenous cytokine productionIFN-g levelsTumor cell heterogeneityFunctional IL-12Blood-brain barrierCombination immunotherapyIT injectionSafety profileIFN-g
2019
Disagreement Between Randomized and Observational Evidence on the Use of Bilateral Internal Thoracic Artery Grafting: A Meta‐Analytic Approach
Gaudino M, Rahouma M, Hameed I, Khan FM, Taggart DP, Flather M, Biondi‐Zoccai G, Fremes SE. Disagreement Between Randomized and Observational Evidence on the Use of Bilateral Internal Thoracic Artery Grafting: A Meta‐Analytic Approach. Journal Of The American Heart Association 2019, 8: e014638. PMID: 31752642, PMCID: PMC6912987, DOI: 10.1161/jaha.119.014638.Peer-Reviewed Original ResearchConceptsInternal thoracic arteryObservational studyThoracic arterySurvival dataBilateral Internal Thoracic Artery GraftingBilateral internal thoracic artery groupBilateral internal thoracic arteryCox regression hazardPropensity-Matched StudyLong-term outcomesMost observational studiesArtery GraftingArtery groupImproved survivalControl armImproved outcomesControl groupSurvival curvesArteryBeneficial effectsMeta-analytic approachSurvivalPatientsExperimental groupOutcomesATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE
Lukas R, Chiocca E, Kurz S, Yu J, Landolfi J, Rao G, Buck J, Demars N, Smith A, Miao J, Zhou J, Wang Y, Gelb A, Cooper L. ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE. Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847372, DOI: 10.1093/neuonc/noz175.018.Peer-Reviewed Original ResearchLow-dose dexamethasoneIL-12IFN-gIntratumoral injection of AdOngoing phase 1Low-dose corticosteroidsIntra-tumoral administrationProduction of IL-12Drug-related toxicityInjection of AdRecombinant IL-12Induce IL-12Overall survivalIntratumoral injectionDose-relatedDrug-related deathsGene therapyHistorical controlsAnticipated survivalSubject characteristicsSurvival dataSurvivalBiomarker studiesBiomarker analysisBiomarkersProgrammed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis
Niglio S, Jia R, Ji J, Ruder S, Patel V, Martini A, Sfakianos J, Marqueen K, Waingankar N, Mehrazin R, Wiklund P, Oh W, Mazumdar M, Ferket B, Galsky M. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology 2019, 76: 782-789. PMID: 31200951, DOI: 10.1016/j.eururo.2019.05.037.Peer-Reviewed Original ResearchConceptsPD-1/PD-L1 inhibitorsMetastatic urothelial cancerPD-L1 blockadePD-1PD-1/PD-L1PD-L1Death-1Urothelial cancerSurvival outcomesPatients treated with PD-1/PD-L1 inhibitorsAnti-programmed death-ligand 1Follow-upPatients treated with PD-1Programmed death ligand 1 blockadeClinical trialsProgrammed death-ligand 1 inhibitorAnti-programmed death-1PD-1/PD-L1 blockadeSurvival dataAnti-PD-1Assessed PD-1PD-L1 inhibitorsProgrammed death-1Death-ligand 1PD-L1 inhibitionMature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
Rosenberg J, Sridhar S, Zhang J, Smith D, Ruether J, Flaig T, Baranda J, Lang J, Plimack E, Sangha R, Heath E, Merchan J, Quinn D, Srinivas S, Milowsky M, Wu C, Gartner E, Melhem-Bertrandt A, Petrylak D. Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2019, 37: 377-377. DOI: 10.1200/jco.2019.37.7_suppl.377.Peer-Reviewed Original ResearchMetastatic urothelial cancerTreatment-related AEsLiver metastasesMedian followUrothelial cancerPrimary tumor siteUnmet medical needMedian PFSPrior chemotherapyMonotherapy studiesMedian durationPoor prognosisCombination therapyPlatinum chemotherapyMature resultsDay 1Nectin-4Medical needTumor siteSecondary objectivePhase IAntitumor activityEncouraging responseSurvival dataChemotherapySurvival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
Tabakin A, Kim S, Polotti C, Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. Journal Of Clinical Oncology 2019, 37: 534-534. DOI: 10.1200/jco.2019.37.7_suppl.534.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionOverall survival rateTesticular seminomaSurvival rateOverall survivalClinical stagePC settingsUnderwent retroperitoneal lymph node dissectionComprehensive community cancer programsFive-year overall survivalNational Cancer DatabaseCommunity cancer programsFirst-line treatmentLow-volume diseaseLymph node dissectionKaplan-Meier methodSurvival dataAvailable survival dataMajority of menNonseminoma histologyPrior chemotherapyNode dissectionSeminoma patientsFinal cohortOngoing trials
2018
Survival Modeling of Pancreatic Cancer with Radiology Using Convolutional Neural Networks
Muhammad H, Häggström I, Klimstra D, Fuchs T. Survival Modeling of Pancreatic Cancer with Radiology Using Convolutional Neural Networks. Lecture Notes In Computer Science 2018, 11042: 187-192. DOI: 10.1007/978-3-030-01045-4_23.Peer-Reviewed Original ResearchConvolutional neural networkRGB-channel imagesSegmentation of organsPancreatic cancerConvolutional layersComputed tomographyNeural networkPre-trainingModel of pancreatic cancerEarly detection of pancreatic cancerCT imagesDetection of pancreatic cancerPersonalized treatment decisionsGrand challengeMICCAI grand challengeCT slicesConcordance indexNon-invasive imagingDisease progressionTreatment decisionsMorphological signaturesSurvival modelsCancerSurvival data
2017
Complete hazard ranking to analyze right-censored data: An ALS survival study
Huang Z, Zhang H, Boss J, Goutman S, Mukherjee B, Dinov I, Guan Y. Complete hazard ranking to analyze right-censored data: An ALS survival study. PLOS Computational Biology 2017, 13: e1005887. PMID: 29253881, PMCID: PMC5749893, DOI: 10.1371/journal.pcbi.1005887.Peer-Reviewed Original ResearchTreatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature
Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology 2017, 93: 249-258. PMID: 28746931, PMCID: PMC5617794, DOI: 10.1159/000478050.Peer-Reviewed Original ResearchConceptsMUP patientsProspective melanoma databaseSystemic therapyUnknown primaryMetastatic melanomaClinical trialsSingle-institution studyMKP patientsTreatment guidelinesPoor outcomeMelanoma databaseWorse outcomesTreatment outcomesPatientsBetter outcomesTherapyPatient dataMelanomaGoogle ScholarUnique populationSurvival dataOutcomesLimited dataImmunotherapyTrials
2016
Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer
Wei R, De Vivo I, Huang S, Zhu X, Risch H, Moore JH, Yu H, Garmire LX. Meta-dimensional data integration identifies critical pathways for susceptibility, tumorigenesis and progression of endometrial cancer. Oncotarget 2016, 7: 55249-55263. PMID: 27409342, PMCID: PMC5342415, DOI: 10.18632/oncotarget.10509.Peer-Reviewed Original ResearchConceptsEndometrial cancerEC riskSusceptible pathwaysCancer Genome Atlas (TCGA) samplesProgression of ECEndometrial Cancer StudyCommon female cancerGenome-wide association studiesEC cohortFemale cancersCell cycle pathwayCancerP53 signalingCommon pathwayGenetic polymorphismsCancer studiesSurvival dataProgressionCritical pathwaysGenetic information processing pathwaysMulti-omics analysisTumorigenesisCycle pathwayMetabolism pathwaysRisk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply